Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140101 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
A Phase 2 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,099
- Enrollment target
NCT00140101: Completed Phase 2 study, sponsored by Abbott Medical Devices.
NCT00140101 is a Phase 2 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,099 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (726% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00140101, a Phase 2 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,099 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries. The study is designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that has proven superior to bare metal stents and is a recognized standard of care.
Interventions
- DEVICE TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- DEVICE ZoMaxx™ Drug-Eluting Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,099 participants |
| Start Date | 2005-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
What the finished NCT00140101 record still lists
NCT00140101 is an interventional study that assigns participants to a tested intervention. Its 1,099 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (726% higher).
The record links to 0 conditions, and to 2 interventions - of which TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent is the first listed.
NCT00140101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00140101 about?
NCT00140101 is a clinical study titled "Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries". The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries. The study is designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that has proven superior to bare metal stent...
What is the current status of trial NCT00140101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,099 participants. The study started on 2005-05. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00140101?
The interventions under investigation include: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent (DEVICE), ZoMaxx™ Drug-Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT00140101?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00140101's enrollment target sits among peer trials
1,099 22nd of 2000 higher than 1,979 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia